CALC · Insider Trading
CalciMedica, Inc. Common Stock
Every open-market purchase and sale reported by CALC officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-05 | Evgeny Zaytsev | Director | A | +20,000 deriv. | — |
| 2026-10-05 | Frederic Guerard | Director | A | +20,000 deriv. | — |
| 2026-10-05 | Alan Glicklich | Director | A | +20,000 deriv. | — |
| 2026-10-05 | Robert N Wilson | Director | A | +20,000 deriv. | — |
| 2026-10-05 | Allan Shaw | Director | A | +20,000 deriv. | — |
| 2026-09-28 | Sudarshan Hebbar | Chief Medical Officer | A | +180,000 deriv. | — |
| 2026-09-28 | A. Rachel Leheny | CHIEF EXECUTIVE OFFICER | A | +360,000 deriv. | — |
| 2026-09-28 | Kenneth A. Stauderman | Chief Scientific Officer | A | +180,000 deriv. | — |
| 2026-09-28 | Stephen Bardin | Chief Financial Officer | A | +190,000 deriv. | — |
| 2026-08-24 | ALAFI CAPITAL CO LLC | 10%+ Owner | A | — | — |
| 2026-08-21 | A. Rachel Leheny | CHIEF EXECUTIVE OFFICER | A | +373,458 deriv. | — |
| 2026-08-21 | Eric W Roberts | CHIEF BUSINESS OFFICER | A | +373,458 deriv. | — |
| 2026-08-21 | Allan Shaw | Director | A | +10,000 deriv. | — |
| 2026-08-21 | Evgeny Zaytsev | Director | A | +2,910,534 deriv. | — |
| 2026-08-21 | Alan Glicklich | Director | A | +10,000 deriv. | — |
| 2026-08-21 | Sudarshan Hebbar | Chief Medical Officer | A | +248,972 deriv. | — |
| 2026-08-21 | Frederic Guerard | Director | A | +10,000 deriv. | — |
| 2026-08-21 | Robert N Wilson | Director | A | +2,375,242 deriv. | — |
| 2026-07-07 | Evgeny Zaytsev | Director | A | +20,000 deriv. | — |
| 2026-06-29 | Sudarshan Hebbar | Chief Medical Officer | A | +124,486 | +$100.00K |
| 2026-06-29 | Robert N Wilson | Director | A | +1,182,621 | +$950.00K |
| 2026-06-29 | A. Rachel Leheny | CHIEF EXECUTIVE OFFICER | A | +186,729 | +$150.00K |
| 2026-06-29 | Fred A Middleton | Director | Buy | +248,972 | +$200.00K |
| 2026-06-29 | Eric W Roberts | CHIEF BUSINESS OFFICER | A | +186,729 | +$150.00K |
| 2026-04-07 | Stephen Bardin | Chief Financial Officer | A | +67,728 deriv. | — |
| 2026-04-07 | Sudarshan Hebbar | Chief Medical Officer | A | +91,173 deriv. | — |
| 2026-04-07 | Michael J. Dunn | President and COO | A | +65,124 deriv. | — |
| 2026-04-07 | Eric W Roberts | CHIEF BUSINESS OFFICER | A | +83,358 deriv. | — |
| 2026-04-07 | A. Rachel Leheny | CHIEF EXECUTIVE OFFICER | A | +148,482 deriv. | — |
| 2026-04-07 | Kenneth A. Stauderman | Chief Scientific Officer | A | +65,124 deriv. | — |
| 2025-10-14 | Alan Glicklich | Director | A | +937 deriv. | — |
| 2025-09-22 | Eric W Roberts | CHIEF BUSINESS OFFICER | Buy | +2,500 | +$7.67K |
| 2025-09-17 | Eric W Roberts | CHIEF BUSINESS OFFICER | Buy | +3,400 | +$9.10K |
| 2025-09-15 | Eric W Roberts | CHIEF BUSINESS OFFICER | Buy | +5,000 | +$15.60K |
| 2025-09-11 | Eric W Roberts | CHIEF BUSINESS OFFICER | Buy | +2,343 | +$7.38K |
| 2025-09-02 | Eric W Roberts | CHIEF BUSINESS OFFICER | Buy | +10,000 | +$28.53K |
| 2025-08-25 | Eric W Roberts | CHIEF BUSINESS OFFICER | Buy | +3,508 | +$9.80K |
| 2025-08-21 | Sudarshan Hebbar | Chief Medical Officer | Buy | +9,563 | +$26.96K |
| 2025-08-21 | Eric W Roberts | CHIEF BUSINESS OFFICER | MIXED | +18,000 | +$31.18K |
| 2025-08-19 | Eric W Roberts | CHIEF BUSINESS OFFICER | Buy | +5,076 | +$14.71K |
| 2025-08-18 | Sudarshan Hebbar | Chief Medical Officer | Buy | +5,976 | +$16.36K |
| 2025-07-29 | Kenneth A. Stauderman | Chief Scientific Officer | MIXED | — | +$310 |
| 2025-07-23 | Eric W Roberts | CHIEF BUSINESS OFFICER | Buy | +1,500 | +$5.66K |
| 2025-07-22 | Eric W Roberts | CHIEF BUSINESS OFFICER | Buy | +1,500 | +$5.05K |
| 2025-07-21 | A. Rachel Leheny | CHIEF EXECUTIVE OFFICER | Buy | +1,000 | +$3.40K |
| 2025-07-18 | Robert N Wilson | Director | Buy | +4,500 | +$12.91K |
| 2025-07-18 | Eric W Roberts | CHIEF BUSINESS OFFICER | Buy | +2,000 | +$5.76K |
| 2025-07-16 | Eric W Roberts | CHIEF BUSINESS OFFICER | Buy | +6,500 | +$15.81K |
| 2025-07-15 | A. Rachel Leheny | CHIEF EXECUTIVE OFFICER | Buy | +2,500 | +$6.18K |
| 2025-07-10 | Eric W Roberts | CHIEF BUSINESS OFFICER | Buy | +5,000 | +$8.02K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| ALAFI CAPITAL CO LLC | 10%+ Owner | 1,022,469 | $1.33M |
| Robert N Wilson | Director | 320,930 | $417.21K |
| Fred A Middleton | Director | 196,652 | $255.65K |
| Eric W Roberts | CHIEF BUSINESS OFFICER | 136,509 | $177.46K |
| A. Rachel Leheny | CHIEF EXECUTIVE OFFICER | 76,777 | $99.81K |
| Sudarshan Hebbar | Chief Medical Officer | 37,205 | $48.37K |
| Frederic Guerard | Chief Executive Officer | 22,222 | $28.89K |
| Stephen Bardin | Chief Financial Officer | 8,600 | $11.18K |
| Kenneth A. Stauderman | Chief Scientific Officer | 2,589 | $3.37K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CALC quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.